Stockscreener 앱 받기
8.36
4.13%
-0.36
전일 마감가:
$8.72
열려 있는:
$8.75
하루 거래량:
570.09K
Relative Volume:
0.42
시가총액:
$498.31M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-2.70
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
+0.48%
1개월 성능:
-18.36%
6개월 성능:
+105.41%
1년 성능:
+143.73%
1일 변동 폭
$8.325
$8.8999
1주일 범위
$7.79
$9.78
52주 변동 폭
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.36 | 519.77M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Nasdaq Moves: Can Kyverna Therapeutics Inc lead its sector in growth2025 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Decliners: Can Kyverna Therapeutics Inc lead its sector in growthJuly 2025 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
KYTX: First-in-class CAR-T therapy shows durable efficacy in autoimmune diseases, with commercial launch imminent - TradingView — Track All Markets
KYTX: Mivcel delivers unprecedented outcomes in SPS and MG, with BLA filing and commercial launch imminent - TradingView — Track All Markets
Aug Catalysts: Will Kyverna Therapeutics Inc stock benefit from commodity pricesWeekly Trend Recap & Safe Entry Trade Reports - Bộ Nội Vụ
Will Kyverna Therapeutics Inc stock outperform value stocksWeekly Gains Summary & Entry Point Strategy Guides - Bộ Nội Vụ
Published on: 2026-01-13 22:22:40 - Bộ Nội Vụ
Kyverna Therapeutics Names Christi Shaw Executive Board Chair - TipRanks
Cell therapy push targets stiff person syndrome and myasthenia gravis - Stock Titan
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Is Kyverna Therapeutics Inc. stock near bottom after declineRecovery Day Options & HOKA model picks for your routine - Улправда
What dividend safety score for Kyverna Therapeutics Inc. stock2025 Earnings Surprises & Daily Stock Momentum Reports - Улправда
How Kyverna Therapeutics Inc. stock trades before earnings2025 Biggest Moves & Weekly Stock Performance Updates - Улправда
Two-Year-Old Candid Looks To Move Autoimmune TCEs Into Phase II Development - Citeline News & Insights
What margin trends mean for Kyverna Therapeutics Inc. stockWeekly Trade Review & AI Based Buy and Sell Signals - ulpravda.ru
Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Kyverna Therapeutics Inc Stock Analysis and ForecastPortfolio Risk Assessment & Free Strong Return On Assets - Early Times
Kyverna Therapeutics Inc trading halted, volatility trading pause - MSN
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley - MSN
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo - MSN
Kyverna shares jump on strong results from SPS clinical trial - MSN
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
Twin Insider Buys Signal Major Confidence in Kyverna Therapeutics - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares - MarketBeat
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock - MarketBeat
Kyverna Therapeutics director Seidenberg buys $999,997 in shares By Investing.com - Investing.com Nigeria
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 By Investing.com - Investing.com Australia
Kyverna Therapeutics director Seidenberg buys $999,997 in shares - Investing.com
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 - Investing.com
Kyverna Therapeutics Insider Bought Shares Worth $999,998, According to a Recent SEC Filing - marketscreener.com
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 11.68% to 28.76 - Nasdaq
Institution Moves: What margin trends mean for Kyverna Therapeutics Inc. stockForecast Cut & Community Trade Idea Sharing - ulpravda.ru
Why Kyverna Therapeutics Inc. stock is rated strong buy2025 Market Outlook & Weekly Stock Breakout Alerts - Улправда
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Kyverna Therapeutics Inc. stock attractive after correction2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Market Leaders: What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Pullbacks & Accurate Buy Signal Alerts - ulpravda.ru
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Kyverna Therapeutics announces $100 million public offering - MSN
Is Kyverna Therapeutics Inc. stock attractive after correctionDollar Strength & Daily Stock Trend Reports - ulpravda.ru
What is the fair value of Kyverna Therapeutics Inc. stock nowMarket Volume Summary & Real-Time Market Sentiment Alerts - DonanımHaber
Will Kyverna Therapeutics Inc. stock see PE expansionQuarterly Growth Report & Fast Moving Trade Plans - DonanımHaber
Aug PostEarnings: How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Highlights & High Accuracy Investment Signals - ulpravda.ru
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kyverna Therapeutics Inc 주식 (KYTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Westlake BioPartners Opportuni | 10% Owner |
Dec 18 '25 |
Buy |
7.50 |
133,333 |
999,998 |
869,317 |
| Walker Karen Marie | Chief Technology Officer |
Dec 15 '25 |
Option Exercise |
4.83 |
23,998 |
115,910 |
46,634 |
| Walker Karen Marie | Chief Technology Officer |
Dec 15 '25 |
Sale |
12.20 |
23,998 |
292,776 |
22,636 |
4.73%
0.92%
자본화:
|
볼륨(24시간):